|Bid||24.21 x 900|
|Ask||24.24 x 1000|
|Day's Range||24.02 - 25.98|
|52 Week Range||19.38 - 78.00|
|Beta (5Y Monthly)||2.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2022 - Mar 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||86.00|
In a somewhat counterintuitive development, shares of Axsome Therapeutics (NASDAQ: AXSM) rose on Thursday even though the company pointed out several issues in the development of one of its drugs. Following the company's latest update on the affected program, one analyst reiterated his bullish outlook on the shares, and they rose by 5.5%. In a regulatory filing, Axsome said it provided an official response to the Food and Drug Administration (FDA) regarding the pending New Drug Application (NDA) its AXS-05 drug candidate.
Joliet, IL, based Investment company First Midwest Bank Trust Division (Current Portfolio) buys Axsome Therapeutics Inc, PROSHARES TRUST, iShares Russell Mid-Cap ETF, ISHARES TRUST, Aurinia Pharmaceuticals Inc, sells Iovance Biotherapeutics Inc, Consumer Discretionary Select Sector SPDR, AT&T Inc, Avis Budget Group Inc, Cerus Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, First Midwest Bank Trust Division.
Shares of clinical-stage biotech companies can skyrocket in a short period based on positive clinical and regulatory news. With that said, let's look at two clinical-stage biotechs that currently boast significant upside potential if we go by average price targets assigned by Wall Street analysts: CRISPR Therapeutics (NASDAQ: CRSP) and Axsome Therapeutics (NASDAQ: AXSM).